Arne Thiermann
Europe Guide 2024
Band 3 : Life Sciences
Share profile
Band 3
Articles, highlights and press releases
2 items provided by Hogan Lovells International LLP
Hogan Lovells advises Shire in ex-U.S. closing of its US$2.4bn business sale to Servier S.A.S.
Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
Hogan Lovells advises Shire in ex-U.S. closing of its US$2.4bn business sale to Servier S.A.S.
Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
Hogan Lovells advises Shire in ex-U.S. closing of its US$2.4bn business sale to Servier S.A.S.
Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
Hogan Lovells advises Shire in ex-U.S. closing of its US$2.4bn business sale to Servier S.A.S.
Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.